Welcome to our dedicated page for Pds Biotechnology news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology stock.
PDS Biotechnology Corporation reports developments in targeted cancer immunotherapies based on its Versamune platform. Company news centers on PDS0101, also called Versamune HPV, in HPV16-positive head and neck cancer, and on PDS01ADC, an IL-12 fused antibody drug conjugate and tumor-targeted immunocytokine evaluated across multiple solid tumor indications.
Recurring updates include clinical-trial data, National Cancer Institute-led study presentations, FDA and IND protocol communications, scientific publications, patent coverage for core technology, quarterly financial results, and broader corporate-program updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced that its abstract, featuring updated data from the VERSATILE-002 study, has been selected for presentation at the 2023 ASCO Annual Meeting on June 5, 2023. This Phase 2 study investigates the safety and efficacy of PDS0101 combined with KEYTRUDA® in treating patients with HPV16-positive head and neck cancer. The study focuses on two groups: ICI-naïve and ICI-refractory patients. Preliminary results show that 77% of patients had disease stabilization or tumor shrinkage, with an 87% overall survival rate at 9 months. The presentation will be part of the Head and Neck Cancer session, highlighting PDS0101's potential as a targeted therapy for this growing patient demographic.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced it received $1.4 million from the sale of tax benefits to a profitable New Jersey corporation under the New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2021. This funding is crucial as the company transitions its lead asset, PDS0101, into a registrational trial aimed at treating HPV16-positive metastatic or recurrent head and neck cancer. The New Jersey program allows unprofitable tech companies to sell a portion of their net operating losses and R&D tax credits to profitable entities, turning tax credits into cash to support growth, R&D, and operations. PDS Biotech focuses on developing targeted immunotherapies for cancer and infectious diseases utilizing proprietary platforms like Versamune®.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced a Key Opinion Leader (KOL) Roundtable focusing on Interleukin-12 (IL-12) on April 21, 2023, from 8:00 to 9:00 AM ET. This event will explore the potential of PDS0301, a novel IL-12 fusion protein, in oncology. The roundtable, moderated by Dr. Lauren Wood, will feature presentations from notable experts including Dr. James Gulley and Dr. Jeffrey Schlom. PDS0301 aims to enhance T cell activity in the tumor microenvironment while minimizing systemic exposure, thus promising improved safety and tolerability. Registration is open, and a live webcast will be available on the company’s investor relations website. PDS Biotechnology is committed to advancing targeted immunotherapies for cancer and infectious diseases, with PDS0101 entering Phase 3 trials in 2023.
PDS Biotech announced plans to advance PDS0101 into a Phase 3 clinical trial named VERSATILE-003, targeting HPV16-positive recurrent and/or metastatic head and neck cancer in 2023. This initiative aligns with Oral, Head & Neck Cancer Awareness Month in April. The Phase 3 trial follows positive results from a Phase 2 study, which indicated a 41% objective response rate and an 87% overall survival rate at nine months. The combination therapy of PDS0101 with KEYTRUDA received Fast Track designation from the FDA, underscoring its potential in addressing a significant unmet medical need.